Literature DB >> 23895819

Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM).

Yee Weng Wong1, Gregg C Fonarow, Xiaojuan Mi, W Frank Peacock, Roger M Mills, Lesley H Curtis, Laura G Qualls, Adrian F Hernandez.   

Abstract

BACKGROUND: Timing of initial treatment for acute decompensated heart failure (ADHF) varies across hospitals and its impact on outcomes remains poorly defined. We examined the association between time to first intravenous (IV) heart failure (HF) therapy and patient outcomes.
METHODS: Using the ADHERE-EM linked to Medicare claims data, we identified patients ≥65 years old who were hospitalized for ADHF and received IV HF therapy during index admission. Cox proportional hazard model was used to assess the association of time to treatment with a composite of 30-day all-cause mortality or re-admission. Generalized linear mixed models were used to examine the association of time to treatment with in-hospital all-cause mortality, index hospitalization length of stay, and total days alive and out-of-hospital at 30 days.
RESULTS: Of 6,971 patients, the median time to first IV HF therapy was 2.3-hours (interquartile range 1.1, 4.4). The cumulative incidence of 30-day all-cause mortality or readmission was 27.4%. After adjusting for covariates, time to treatment was not associated with increased risk of composite 30-day all-cause mortality or re-admission (HR 1.00; 95% CI 1.00-1.00; P = .221). However, every hour delay in treatment was associated with a modest increased risk of in-hospital mortality (adjusted OR 1.01; 95% CI 1.00-1.02; P = .001) and an approximately 1.4-hour increase in index admission length of stay (P < .001).
CONCLUSION: Among older patients presenting with ADHF, delay in initiating IV HF therapy was associated with modestly higher risk for in-hospital mortality and longer length of stay, but was not associated with 30-day outcomes.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23895819     DOI: 10.1016/j.ahj.2013.05.014

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

Review 1.  CardioMEMS, the real progress in heart failure home monitoring.

Authors:  Edoardo Gronda; Emilio Vanoli; Alessandro Zorzi; Domenico Corrado
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

2.  Prehospital Diagnosis and Treatment of Patients With Acute Heart Failure.

Authors:  Michael Supples; Katelyn Jelden; Jenna Pallansch; Frances M Russell
Journal:  Cureus       Date:  2022-06-12

3.  Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare.

Authors:  Cristal L Brown; Bradley G Hammill; Laura G Qualls; Lesley H Curtis; Andrew J Muir
Journal:  J Pain Symptom Manage       Date:  2016-06-03       Impact factor: 3.612

4.  Preventable delays to intravenous furosemide administration in the emergency department prolong hospitalization for patients with acute heart failure.

Authors:  Michael J Ward; Sean P Collins; Dandan Liu; Craig M Froehle
Journal:  Int J Cardiol       Date:  2018-06-28       Impact factor: 4.164

5.  The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department.

Authors:  Òscar Miró; Pia Harjola; Xavier Rossello; Víctor Gil; Javier Jacob; Pere Llorens; Francisco Javier Martín-Sánchez; Pablo Herrero; Gemma Martínez-Nadal; Sira Aguiló; María Luisa López-Grima; Marta Fuentes; José María Álvarez Pérez; Esther Rodríguez-Adrada; María Mir; Josep Tost; Lluís Llauger; Frank Ruschitzka; Veli-Pekka Harjola; Wilfried Mullens; Josep Masip; Ovidiu Chioncel; W Frank Peacock; Christian Müller; Alexandre Mebazaa
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2021-06-30

6.  Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology.

Authors:  Josep Masip; W Frank Peacok; Mattia Arrigo; Xavier Rossello; Elke Platz; Louise Cullen; Alexandre Mebazaa; Susanna Price; Héctor Bueno; Salvatore Di Somma; Mucio Tavares; Martin R Cowie; Alan Maisel; Christian Mueller; Òsar Miró
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2022-02-08

7.  Congestive heart failure: experimental model.

Authors:  Antonio Francesco Corno; Xue Cai; Caroline B Jones; Giuseppina Mondani; Mark R Boyett; Jonathan Charles Jarvis; George Hart
Journal:  Front Pediatr       Date:  2013-10-28       Impact factor: 3.418

8.  Time Interval from Symptom Onset to Hospital Care in Patients with Acute Heart Failure: A Report from the Tokyo Cardiac Care Unit Network Emergency Medical Service Database.

Authors:  Yasuyuki Shiraishi; Shun Kohsaka; Kazumasa Harada; Tetsuro Sakai; Atsutoshi Takagi; Takamichi Miyamoto; Kiyoshi Iida; Shuzou Tanimoto; Keiichi Fukuda; Ken Nagao; Naoki Sato; Morimasa Takayama
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

Review 9.  Considerations for initial therapy in the treatment of acute heart failure.

Authors:  William F Peacock; Chad M Cannon; Adam J Singer; Brian C Hiestand
Journal:  Crit Care       Date:  2015-11-10       Impact factor: 9.097

Review 10.  The time-to-treatment concept in acute heart failure: Lessons and implications from REALITY-AHF.

Authors:  Nobuyuki Kagiyama; Yuya Matsue
Journal:  Anatol J Cardiol       Date:  2018-08       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.